Schonfeld Strategic Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,813	Closed	-$830K	–	2271
2020 Q4	$830K	Sell	6,813 -13,002	-66%	-$1.42M	0.01%	871
2020 Q3	$1.73M	Buy	19,815 +10,137	+105%	+$706K	0.03%	545
2020 Q2	$625K	Buy	+9,678	New	+$558K	0.02%	732
2020 Q1	–	Sell	-9,700	Closed	-$604K	–	1646
2019 Q4	$604K	Sell	9,700 -81,900	-89%	-$3.9M	0.01%	674
2019 Q3	$3.44M	Buy	+91,600	New	+$3.99M	0.1%	214

Other funds holding TPTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Schonfeld Strategic Advisors's TPTX Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 6,813 shares — an estimated $830K sold.

Schonfeld Strategic Advisors first reported a position in TPTX in Q3 2019 and held it in 5 quarters. The position peaked at $3.44M in Q3 2019. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

Schonfeld Strategic Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 6,813 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $830K.
Schonfeld Strategic Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
Schonfeld Strategic Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.44M in Q3 2019.
202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.